Anorectic state of obesity medications in the United States. Are leaner times ahead?

References

• Thomas CE, Mauer EA, Shukla AP, et al. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016;24(9):1955–1961.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention. 2011.
   Google Scholar
• Centers for Disease Control and Prevention. Overweight and obesity. [cited 2017 Jul 25]. https://www.cdc.gov/obesity/index.html
   Google Scholar
• Del Re AC, Frayne SM, Harris AH. Antiobesity medication use across the veterans health administration: patient-level predictors of receipt. Obesity (Silver Spring). 2014;22(9):1968–1972.
   PubMed Web of Science ®Google Scholar
• Thomas DD, Waring ME, Ameli O, et al. Patient characteristics associated with receipt of prescription weight-management medications among veterans participating in MOVE! Obesity (Silver Spring). 2019;27(7):1168–1176.
   PubMed Web of Science ®Google Scholar
• Halpern B, Halpern A. Why are anti-obesity drugs stigmatized? Expert Opin Drug Saf. 2015;14(2):185–189.
   PubMed Web of Science ®Google Scholar
• Hainer V, Hainerova IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28(Suppl 2):8–20.
   PubMedGoogle Scholar
• Gotthardt JD, Bello NT. Can we win the war on obesity with pharmacotherapy? Expert Rev Clin Pharmacol. 2016;9(10):1289–1297.
   PubMed Web of Science ®Google Scholar
• Neoh SL, Sumithran P, Haywood CJ, et al. Combination phentermine and topiramate for weight maintenance: the first Australian experience. Med J Aust. 2014;201(4):224–226.
   PubMed Web of Science ®Google Scholar
• Nordisk N. OZEMPIC (semaglutide) injection, for subcutaneous use; 2017. www.novo-pi.com/ozempic.pdf
   Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528–539.
   PubMed Web of Science ®Google Scholar
• Chen KY, Muniyappa R, Abel BS, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocrinol Metab. 2015;100(4):1639–1645.
   PubMed Web of Science ®Google Scholar
• Clement K, Biebermann H, Farooqi IS, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551–555.
   PubMed Web of Science ®Google Scholar
• Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013;62(2):490–497.
   PubMed Web of Science ®Google Scholar
• Kuhnen P, Clement K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a Melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240–246.
   PubMed Web of Science ®Google Scholar
• Huang H, Bell KF, Gani R, et al. A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes. Am J Manag Care. 2018;24(8 Suppl):S132–S137.
   PubMed Web of Science ®Google Scholar
• Ambery PD, Klammt S, Posch MG, et al. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, phase 1 study. Br J Clin Pharmacol. 2018;84(10):2325–2335.
   PubMed Web of Science ®Google Scholar
• Ambery P, Parker VE, Stumvoll M, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140):2607–2618.
   PubMed Web of Science ®Google Scholar
• Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Invest Drugs. 2009;10(10):1105–1116.
   PubMedGoogle Scholar
• Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906–1913.
   PubMed Web of Science ®Google Scholar
• Astrup A, Madsbad S, Breum L, et al. Under-reporting of adverse effects of tesofensine. Lancet. 2013;382(9887):127.
   PubMed Web of Science ®Google Scholar
• Lancet T. Expression of concern–effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9873):1167.
   PubMed Web of Science ®Google Scholar
• Bentzen BH, Grunnet M, Hyveled-Nielsen L, et al. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring). 2013;21(5):985–992.
   PubMed Web of Science ®Google Scholar
• Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?. JAMA Intern Med. 2014;174(4):615–619.
   PubMed Web of Science ®Google Scholar
• Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23(4):591–601.
   PubMed Web of Science ®Google Scholar
• Tan T, Behary P, Tharakan G, et al. The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers. J Clin Endocrinol Metab. 2017;102(7):2364–2372.
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. Bmj. 2007;335(7631):1194–1199.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
   PubMed Web of Science ®Google Scholar
• Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306–313.
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–342.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Adminstration. Risk of oral clefts in children born to mothers taking Topamx (topiramate). FDA Drug Saf Commun. 2011;[03-04-2011].
   Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256.
   PubMed Web of Science ®Google Scholar
• Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6(4):560–567.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843–854.
   PubMed Web of Science ®Google Scholar